Chinese General Practice ›› 2023, Vol. 26 ›› Issue (18): 2286-2292.DOI: 10.12114/j.issn.1007-9572.2022.0861
• Evidence-based Medicine • Previous Articles Next Articles
Received:
2022-10-21
Revised:
2023-02-05
Published:
2023-06-20
Online:
2023-02-27
Contact:
YAO Ping
通讯作者:
姚萍
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0861
第一作者 | 发表时间(年) | 癌症类型 | 国家 | 研究起止时间 | FFQ条目(项) | DII成分(个) | 样本量(病例组/对照组,例) | 性别(男/女) | 协变量调整 | NOS评分(分) | |
---|---|---|---|---|---|---|---|---|---|---|---|
病例组 | 对照组 | ||||||||||
ABE[ | 2018 | 食管癌 | 日本 | 2001年1月至2005年1月 | 47 | 19 | 433/1 296 | 376/57 | 1 122/174 | ⑥⑦ | 7 |
SHIVAPPA[ | 2015 | 食管癌 | 伊朗 | NA | 125 | 27 | 47/96 | 18/29 | 38/58 | ①②③⑥⑦⑨⑫ | 7 |
SHIVAPPA[ | 2015 | 食管癌 | 意大利 | 1992—1997年 | 78 | 31 | 304/743 | 275/29 | 593/150 | ①②③④⑤⑥⑦⑧⑨⑬ | 8 |
LU[ | 2016 | 食管癌 | 瑞典 | 1994年12月至1997年1月 | 63 | 36 | 594/806 | 488/106 | 667/139 | ①②③④⑥⑦⑨⑩ | 8 |
SHIVAPPA[ | 2016 | 胃癌 | 意大利 | 1997—2007年 | 78 | 31 | 230/547 | 143/87 | 286/261 | ④⑤⑥⑧⑨ | 8 |
LEE[ | 2017 | 胃癌 | 韩国 | 2011年3月至2014年1月 | 106 | 35 | 388/776 | 249/139 | 498/278 | ①④⑥⑦⑨⑩⑪ | 7 |
SHIVAPPA[ | 2017 | 食管癌 | 爱尔兰 | 2002—2005年 | 101 | 25 | 224/256 | 189/35 | 216/40 | ①②③④⑥⑦⑨⑪⑫⑬ | 7 |
TANG[ | 2018 | 食管癌 | 中国 | 2008年1月至2009年1月 | 137 | 23 | 359/380 | 260/99 | 269/111 | ①②③④⑥⑦⑧⑩ | 8 |
VAHID[ | 2018 | 胃癌 | 伊朗 | 2014年12月至2015年5月 | 168 | 31 | 82/95 | 37/45 | 43/52 | ①②③④⑥⑦⑧⑨⑪⑬ | 8 |
KIM[ | 2020 | 胃癌 | 韩国 | 2011年3月至2014年1月 | 106 | 35 | 373/752 | 242/131 | 487/265 | ④⑥⑨⑩ | 8 |
BAREKIAI[ | 2022 | 胃癌 | 阿富汗 | 2019年 | 103 | 29 | 90/180 | 66/24 | 131/49 | ②③④⑥⑨⑩⑪ | 6 |
Table 1 Baseline characteristics and quality evaluation using the Newcastle-Ottawa Scale for included studies
第一作者 | 发表时间(年) | 癌症类型 | 国家 | 研究起止时间 | FFQ条目(项) | DII成分(个) | 样本量(病例组/对照组,例) | 性别(男/女) | 协变量调整 | NOS评分(分) | |
---|---|---|---|---|---|---|---|---|---|---|---|
病例组 | 对照组 | ||||||||||
ABE[ | 2018 | 食管癌 | 日本 | 2001年1月至2005年1月 | 47 | 19 | 433/1 296 | 376/57 | 1 122/174 | ⑥⑦ | 7 |
SHIVAPPA[ | 2015 | 食管癌 | 伊朗 | NA | 125 | 27 | 47/96 | 18/29 | 38/58 | ①②③⑥⑦⑨⑫ | 7 |
SHIVAPPA[ | 2015 | 食管癌 | 意大利 | 1992—1997年 | 78 | 31 | 304/743 | 275/29 | 593/150 | ①②③④⑤⑥⑦⑧⑨⑬ | 8 |
LU[ | 2016 | 食管癌 | 瑞典 | 1994年12月至1997年1月 | 63 | 36 | 594/806 | 488/106 | 667/139 | ①②③④⑥⑦⑨⑩ | 8 |
SHIVAPPA[ | 2016 | 胃癌 | 意大利 | 1997—2007年 | 78 | 31 | 230/547 | 143/87 | 286/261 | ④⑤⑥⑧⑨ | 8 |
LEE[ | 2017 | 胃癌 | 韩国 | 2011年3月至2014年1月 | 106 | 35 | 388/776 | 249/139 | 498/278 | ①④⑥⑦⑨⑩⑪ | 7 |
SHIVAPPA[ | 2017 | 食管癌 | 爱尔兰 | 2002—2005年 | 101 | 25 | 224/256 | 189/35 | 216/40 | ①②③④⑥⑦⑨⑪⑫⑬ | 7 |
TANG[ | 2018 | 食管癌 | 中国 | 2008年1月至2009年1月 | 137 | 23 | 359/380 | 260/99 | 269/111 | ①②③④⑥⑦⑧⑩ | 8 |
VAHID[ | 2018 | 胃癌 | 伊朗 | 2014年12月至2015年5月 | 168 | 31 | 82/95 | 37/45 | 43/52 | ①②③④⑥⑦⑧⑨⑪⑬ | 8 |
KIM[ | 2020 | 胃癌 | 韩国 | 2011年3月至2014年1月 | 106 | 35 | 373/752 | 242/131 | 487/265 | ④⑥⑨⑩ | 8 |
BAREKIAI[ | 2022 | 胃癌 | 阿富汗 | 2019年 | 103 | 29 | 90/180 | 66/24 | 131/49 | ②③④⑥⑨⑩⑪ | 6 |
分组依据 | 研究数量(篇) | 异质性检验 | OR(95%CI) | 组间异质性 | ||
---|---|---|---|---|---|---|
P值 | I2值(%) | P值 | I2值(%) | |||
地域 | 0.400 | 0 | ||||
亚洲 | 7[ | 0.04 | 55 | 1.98(1.55,2.53) | ||
欧洲 | 4[ | 0.94 | 0 | 2.31(1.78,3.00) | ||
性别 | 0.007 | 86.7 | ||||
男 | 3[ | 0.24 | 30 | 1.27(0.89,1.83) | ||
女 | 3[ | 0.81 | 0 | 2.61(1.79,3.79) | ||
食管癌病理分型 | 0.930 | 0 | ||||
鳞癌 | 5[ | 0.004 | 74 | 2.68(1.74,4.13) | ||
腺癌 | 2[ | 0.17 | 47 | 2.59(1.44,4.69) | ||
Hp感染 | 0.280 | 14.2 | ||||
阴性 | 3[ | 0.39 | 0 | 1.47(1.08,1.99) | ||
阳性 | 3[ | 0.47 | 0 | 1.90(1.33,2.71) | ||
FFQ方式 | 0.002 | 84.3 | ||||
自我管理 | 3[ | 0.62 | 0 | 1.68(1.53,1.85) | ||
面试官管理 | 3[ | 0.28 | 22 | 2.95(1.96,4.43) | ||
未提及 | 5[ | 0.86 | 0 | 2.41(1.88,3.08) | ||
DII成分数量 | 0.600 | 0 | ||||
>30个 | 6[ | 0.16 | 37 | 2.01(1.57,2.57) | ||
<30个 | 5[ | 0.06 | 56 | 2.25(1.58,3.22) | ||
总能量摄入调整 | 0.010 | 84.6 | ||||
是 | 8[ | 0.30 | 17 | 2.23(1.85,2.68) | ||
否 | 3[ | 0.27 | 25 | 1.70(1.53,1.88) |
Table 2 Subgroup analyses results for DII and UGIC risk
分组依据 | 研究数量(篇) | 异质性检验 | OR(95%CI) | 组间异质性 | ||
---|---|---|---|---|---|---|
P值 | I2值(%) | P值 | I2值(%) | |||
地域 | 0.400 | 0 | ||||
亚洲 | 7[ | 0.04 | 55 | 1.98(1.55,2.53) | ||
欧洲 | 4[ | 0.94 | 0 | 2.31(1.78,3.00) | ||
性别 | 0.007 | 86.7 | ||||
男 | 3[ | 0.24 | 30 | 1.27(0.89,1.83) | ||
女 | 3[ | 0.81 | 0 | 2.61(1.79,3.79) | ||
食管癌病理分型 | 0.930 | 0 | ||||
鳞癌 | 5[ | 0.004 | 74 | 2.68(1.74,4.13) | ||
腺癌 | 2[ | 0.17 | 47 | 2.59(1.44,4.69) | ||
Hp感染 | 0.280 | 14.2 | ||||
阴性 | 3[ | 0.39 | 0 | 1.47(1.08,1.99) | ||
阳性 | 3[ | 0.47 | 0 | 1.90(1.33,2.71) | ||
FFQ方式 | 0.002 | 84.3 | ||||
自我管理 | 3[ | 0.62 | 0 | 1.68(1.53,1.85) | ||
面试官管理 | 3[ | 0.28 | 22 | 2.95(1.96,4.43) | ||
未提及 | 5[ | 0.86 | 0 | 2.41(1.88,3.08) | ||
DII成分数量 | 0.600 | 0 | ||||
>30个 | 6[ | 0.16 | 37 | 2.01(1.57,2.57) | ||
<30个 | 5[ | 0.06 | 56 | 2.25(1.58,3.22) | ||
总能量摄入调整 | 0.010 | 84.6 | ||||
是 | 8[ | 0.30 | 17 | 2.23(1.85,2.68) | ||
否 | 3[ | 0.27 | 25 | 1.70(1.53,1.88) |
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[25] |
|
[26] |
|
[27] |
|
[28] |
|
[29] |
|
[30] |
|
[31] |
|
[32] |
|
[33] |
|
[34] |
|
[35] |
|
[36] |
|
[37] |
|
[38] |
|
[39] |
|
[40] |
|
[41] |
|
[42] |
|
[43] |
|
[44] |
|
[1] | LIU Ailing, ZHOU Jingjing, LI Chengcheng, HE Kaiyue, LIANG Shanshan, ZHOU Shangcheng. Analysis of the Disease Burden Trends and Death Projections for Esophageal Cancer Attributable to Tobacco in China from 1990 to 2019 [J]. Chinese General Practice, 2023, 26(36): 4587-4594. |
[2] | XIE Xuemei, GAO Jing, BAI Dingxi, LU Xianying, HE Jiali, LI Yue. Current Status of Polypharmacy in the Elderly and Its Influencing Factors: a Meta-analysis [J]. Chinese General Practice, 2023, 26(35): 4394-4403. |
[3] | WANG Yue, CHEN Qing, LIU Lurong. Detection Rate of Depression and Its Influencing Factors in Chinese Elderly: a Meta-analysis [J]. Chinese General Practice, 2023, 26(34): 4329-4335. |
[4] | WANG Zhe, DONG Zhihao, ZHENG Hao, KONG Wencheng, ZHANG Yukuan, ZHANG Qiuyue, HAN Jing. Construction of Optimized Treatment Plan of Acupuncture for Migraine Based on Entropy Weight-TOPSIS Method [J]. Chinese General Practice, 2023, 26(34): 4336-4342. |
[5] | ZHANG Jifang, CHEN Fang, TANG Jiawen, LI Hongliang. Predictive Value of Tumor Budding and Tumor-infiltrating Lymphocytes on Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma [J]. Chinese General Practice, 2023, 26(32): 4038-4042. |
[6] | JIAN Qiufeng, XU Ronghua, YAO Qian, ZHOU Yuanyuan. A Meta-analysis of the Prevalence and Influencing Factors of Post-stroke Cognitive Impairment in Chinese Elderly Patients [J]. Chinese General Practice, 2023, 26(32): 4070-4079. |
[7] | JIA Yu, ZHOU Zitong, CAO Xuehua, HU Wanqin, XIANG Feng, XIONG Langyu, WANG Xiaoxia. Incidence of Perimenopausal Syndrome in Chinese Women Aged 40 to 65 Years: a Meta-analysis [J]. Chinese General Practice, 2023, 26(32): 4080-4088. |
[8] | LI Jixin, QIU Linjie, REN Yan, WANG Wenru, LI Meijie, ZHANG Jin. The Correlation of Dietary Inflammatory Index with Overweight, Obesity and Abdominal Obesity: a Meta-analysis [J]. Chinese General Practice, 2023, 26(32): 4089-4097. |
[9] | HE Jingyi, WANG Fang, SHUI Xiaoling, LI Ling, LIANG Qian. Efficacy of Non-pharmacological Interventions to Improve Perimenopausal Insomnia Symptoms: a Network Meta-analysis [J]. Chinese General Practice, 2023, 26(31): 3963-3974. |
[10] | ZHANG Dongli, SHEN Chong, ZHANG Weichuan, CHEN Haibin, ZHAO Jianjun. Efficacy and Safety of Programmed Death-1/Programmed Death-1 Ligand Inhibitors in the Treatment of Renal Cell Cancer: a Meta-analysis [J]. Chinese General Practice, 2023, 26(30): 3815-3822. |
[11] | ZHANG Ming, XU Jing, SUN Zhenhua, ZHAO Wenhao, MA Yingqian, ZHANG Jianqiao, SHEN Haiping. Improvement of Nutritional Status of Elderly Patients with Severe Obstruction Esophageal Carcinoma by Image-guided Photodynamic Therapy [J]. Chinese General Practice, 2023, 26(30): 3780-3784. |
[12] | LI Jilei, LI Honglin, XU Yanchao, LIU Yanan, CHEN Mengli, SHAO Shuai, MA Chunzheng. Clinical Study on the Combination of Xiaotan Huayu Tongyi Granules, Channel Kaijie Pills and Chemotherapy in the Treatment of Esophageal Cancer [J]. Chinese General Practice, 2023, 26(30): 3759-3764. |
[13] | ZHENG Yuling, ZHANG Yaling, LIU Huaimin, XU Yanchao, JIA Xiaolin, LI Junsai, HE Wenlong, TONG Xinduo, QIN Shanwen, ZHANG Lihan. Clinical Observation of Dingxiang Guanshitong Hanhua Pills Alone and Its Combination with Fugui Guanshitong Granules in the Treatment of Advanced Esophageal Cancer [J]. Chinese General Practice, 2023, 26(30): 3765-3771. |
[14] | WEN Wen, ZHANG Kainan, CHEN Yulan, LI Yu, ZHANG Xiangyang. Correlation of Metabolic Indexes as Predictors with Obstructive Sleep Apnea [J]. Chinese General Practice, 2023, 26(30): 3740-3747. |
[15] | ZHU Lin, GUO Yankui, GAO Chen, CHEN Xuezhi, WANG Fashuai. Efficacy of Western Medicine, Chinese Patent Medicine and Their Combination on Post-stroke Insomnia: a Network Meta-analysis [J]. Chinese General Practice, 2023, 26(30): 3823-3832. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||